Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab for HSCT-associated thrombotic microangiopathy (Phase 3)
2020-000144-61Phase 3Active
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in transplant-associated thrombotic microangiopathy (TA-TMA) and thrombotic microangiopathies (TMA) comparing Ravulizumab plus best supportive care with Best supportive care only (2 arms). Primary endpoint: TMA response. Started Jul 2020; status: active.
02
Drugs
ravulizumab
03
Conditions
transplant-associated thrombotic microangiopathy (TA-TMA)thrombotic microangiopathies (TMA)
Beyond the preview
Go deeper on 2020-000144-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000144-61.